Genome-wide copy number alteration and VEGFA amplification of circulating cell-free DNA as a biomarker in advanced hepatocellular carcinoma patients treated with Sorafenib

BACKGROUND: Although sorafenib is the global standard first-line systemic treatment for unresectable hepatocellular carcinoma (HCC), it does not have reliable predictive or prognostic biomarkers. Circulating cell-free DNA (cfDNA) has shown promise as a biomarker for various cancers. We investigated...

Descripción completa

Detalles Bibliográficos
Autores principales: Oh, Chung Ryul, Kong, Sun-Young, Im, Hyeon-Su, Kim, Hwa Jung, Kim, Min Kyeong, Yoon, Kyong-Ah, Cho, Eun-Hae, Jang, Ja-Hyun, Lee, Junnam, Kang, Jihoon, Park, Sook Ryun, Ryoo, Baek-Yeol
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6444867/
https://www.ncbi.nlm.nih.gov/pubmed/30935424
http://dx.doi.org/10.1186/s12885-019-5483-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6444867/
https://www.ncbi.nlm.nih.gov/pubmed/30935424
http://dx.doi.org/10.1186/s12885-019-5483-x

Ejemplares similares